ADMA BIOLOGICS, INC. Revenue
ADMA BIOLOGICS, INC. (ADMA) reported Revenue of $124.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-05
- ADMA BIOLOGICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $124.39M, a 1.98% increase year-over-year.
- ADMA BIOLOGICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $114.49M, a 0.27% decline year-over-year.
- ADMA BIOLOGICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $139.16M, a 18.39% increase year-over-year.
- ADMA BIOLOGICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $134.22M, a 12.00% increase year-over-year.
- ADMA BIOLOGICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $510.17M, a 19.63% increase from fiscal 2024.
- ADMA BIOLOGICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $426.45M, a 65.15% increase from fiscal 2023.
- ADMA BIOLOGICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $258.21M, a 67.59% increase from fiscal 2022.
- ADMA BIOLOGICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $154.08M, a 90.36% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $124.39M 10-Q · filed 2026-08-05 | $238.89M 10-Q · filed 2026-08-05 | $378.05M derived: sum of 3 quarters · filed 2026-08-05 | $512.27M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $114.49M 10-Q · filed 2026-05-06 | $253.66M derived: sum of 2 quarters · filed 2026-05-06 | $387.88M derived: sum of 3 quarters · filed 2026-05-06 | $509.86M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $139.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $273.39M derived: sum of 2 quarters · filed 2026-02-25 | $395.37M derived: sum of 3 quarters · filed 2026-08-05 | $510.17M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | $134.22M 10-Q · filed 2025-11-05 | $256.21M derived: sum of 2 quarters · filed 2026-08-05 | $371.01M 10-Q · filed 2025-11-05 | $488.56M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $121.98M 10-Q · filed 2026-08-05 | $236.79M 10-Q · filed 2026-08-05 | $354.33M derived: sum of 3 quarters · filed 2026-08-05 | $474.17M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $114.80M 10-Q · filed 2026-05-06 | $232.35M derived: sum of 2 quarters · filed 2026-05-06 | $352.19M derived: sum of 3 quarters · filed 2026-05-06 | $459.38M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $117.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $237.39M derived: sum of 2 quarters · filed 2026-02-25 | $344.58M derived: sum of 3 quarters · filed 2026-02-25 | $426.45M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $119.84M 10-Q · filed 2025-11-05 | $227.03M derived: sum of 2 quarters · filed 2025-11-05 | $308.90M 10-Q · filed 2025-11-05 | $382.81M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | $107.19M 10-Q · filed 2025-08-06 | $189.07M 10-Q · filed 2025-08-06 | $262.97M derived: sum of 3 quarters · filed 2026-02-25 | $330.25M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | $81.88M 10-Q · filed 2025-05-07 | $155.78M derived: sum of 2 quarters · filed 2026-02-25 | $223.05M derived: sum of 3 quarters · filed 2026-02-25 | $283.18M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | $73.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $141.18M derived: sum of 2 quarters · filed 2026-02-25 | $201.30M derived: sum of 3 quarters · filed 2026-02-25 | $258.21M 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | $67.28M 10-Q · filed 2024-11-07 | $67.27M 10-Q · filed 2023-11-08 | $127.40M derived: sum of 2 quarters · filed 2024-11-07 | $184.31M 10-Q · filed 2024-11-07 | $184.31M 10-Q · filed 2023-11-08 | $234.29M derived: sum of 4 quarters · filed 2025-03-18 | ||
| 2023-06-30 | $60.12M 10-Q · filed 2024-08-08 | $60.12M 10-Q · filed 2023-08-09 | $117.04M 10-Q · filed 2024-08-08 | $117.04M 10-Q · filed 2023-08-09 | $167.02M derived: sum of 3 quarters · filed 2025-03-18 | $208.11M derived: sum of 4 quarters · filed 2025-03-18 | ||
| 2023-03-31 | $56.91M 10-Q · filed 2024-05-09 | $56.91M 10-Q · filed 2023-05-10 | $106.90M derived: sum of 2 quarters · filed 2025-03-18 | $147.99M derived: sum of 3 quarters · filed 2025-03-18 | $181.89M derived: sum of 4 quarters · filed 2025-03-18 | |||
| 2022-12-31 | $49.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $91.07M derived: sum of 2 quarters · filed 2025-03-18 | $124.98M derived: sum of 3 quarters · filed 2025-03-18 | $154.08M 10-K · filed 2025-03-18 | $154.08M 10-K · filed 2023-03-23 | |||
| 2022-09-30 | $41.09M 10-Q · filed 2023-11-08 | $75.00M derived: sum of 2 quarters · filed 2023-11-08 | $104.10M 10-Q · filed 2023-11-08 | $130.48M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-06-30 | $33.91M 10-Q · filed 2023-08-09 | $63.01M 10-Q · filed 2023-08-09 | $89.39M derived: sum of 3 quarters · filed 2024-02-28 | $110.07M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-03-31 | $29.10M 10-Q · filed 2023-05-10 | $55.49M derived: sum of 2 quarters · filed 2024-02-28 | $76.17M derived: sum of 3 quarters · filed 2024-02-28 | $94.00M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2021-12-31 | $26.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $47.06M derived: sum of 2 quarters · filed 2024-02-28 | $64.89M derived: sum of 3 quarters · filed 2024-02-28 | $80.94M 10-K · filed 2024-02-28 | $80.94M 10-K · filed 2022-03-24 | |||
| 2021-09-30 | $20.68M 10-Q · filed 2022-11-09 | $38.51M derived: sum of 2 quarters · filed 2022-11-09 | $54.56M 10-Q · filed 2022-11-09 | $68.52M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $17.83M 10-Q · filed 2022-08-10 | $33.88M 10-Q · filed 2022-08-10 | $47.84M derived: sum of 3 quarters · filed 2022-08-10 | $58.11M derived: sum of 4 quarters · filed 2022-08-10 | ||||
| 2021-03-31 | $16.05M 10-Q · filed 2022-05-11 | $30.00M derived: sum of 2 quarters · filed 2022-05-11 | $40.28M derived: sum of 3 quarters · filed 2022-05-11 | $48.07M derived: sum of 4 quarters · filed 2022-05-11 | ||||
| 2020-12-31 | $13.96M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $24.23M derived: sum of 2 quarters · filed 2022-03-24 | $32.02M derived: sum of 3 quarters · filed 2022-03-24 | $42.22M 10-K · filed 2022-03-24 | ||||
| 2020-09-30 | $10.28M 10-Q · filed 2021-11-10 | $18.06M derived: sum of 2 quarters · filed 2021-11-10 | $28.26M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $7.79M 10-Q · filed 2021-08-11 | $17.99M 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |